Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma
Gastroesophageal junction (GEJ) adenocarcinoma is an increasingly common cancer with complex biology and poor prognosis. The treatment strategy for locally advanced tumors involves multimodal treatment with perioperative chemotherapy. However, survival rates remain low, especially for advanced disease. Here, formalin-fixed paraffin-embedded tumor sections from 72 patients with GEJ I and II adenocarcinoma who underwent primary resection or perioperative standard-of-care FLOT treatment were analyzed for their intratumoral T cell composition using multiplex immunohistochemistry. The proportions of T cells and their influence on survival were evaluated using Mann-Whitney <i>U</i> and log rank analyses. A comparison of short- and long-term survivors revealed significant differences in the infiltration of regulatory T cells (Tregs). Tumors after neoadjuvant FLOT treatment presented increased proportions of CD8<sup>+</sup> T cells with reduced Granzyme B expression, indicating an altered immune response. Overall survival analysis revealed that high infiltration of Tregs was associated with poor survival. Notably, responders to FLOT therapy had a greater T cell frequency and improved survival, whereas nonresponders presented higher levels of Tregs and CD8<sup>+</sup> T cells expressing TIM-3. Overall, GEJ cancer patients had increased CD8<sup>+</sup> T cells after neoadjuvant chemotherapy with FLOT, and Tregs were associated with treatment response and reduced survival.
Authors
- Daniel E. Stange (ORCID: https://orcid.org/0000-0003-4246-2230)
- Heike Polster
- Jürgen Weitz (ORCID: https://orcid.org/0000-0002-5760-6391)
- Felix Merboth (ORCID: https://orcid.org/0000-0003-2540-6421)
- Sascha Brückmann
- David Digomann (ORCID: https://orcid.org/0000-0002-2139-9183)
- Loreen Natusch (ORCID: https://orcid.org/0009-0002-2144-552X)
- Franziska Baenke (ORCID: https://orcid.org/0000-0001-9389-4688)
- Lena Seifert (ORCID: https://orcid.org/0000-0003-4763-8127)
- Daniela Ellen Aust (ORCID: https://orcid.org/0000-0002-4867-8852)
- Adrian M. Seifert (ORCID: https://orcid.org/0000-0002-5329-3164)
- Marc Schmitz (ORCID: https://orcid.org/0000-0003-3417-6736)
- Luise Rupp (ORCID: https://orcid.org/0000-0002-6610-326X)
- Antonia Stammberger (ORCID: https://orcid.org/0009-0005-1280-967X)
- Ulrich Sommer (ORCID: https://orcid.org/0000-0002-1970-1072)
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- Institute of Immunology (HR)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- OncoImmunology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1080/2162402x.2025.2574859
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05